Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Wednesday, February 10, 2010, 7:30am EST - Canadian Markets open in 2 hours.
To create a watchlist or portfolio of shares,
Sign-in
or
Register
Finance Home
Investing
Volume Leaders
Local Markets
US Markets
International Markets
Advances & Declines
ETFs
Income Trust News
News & Opinion
Markets
Industry
RSS-My Yahoo!
Personal Finance
Banking & Budgeting
Calculators
Insurance
Retirement
Taxes
My Portfolios
Sign In to Create/Edit My Portfolios
Get Quotes
Symbol Lookup
Exchanges
Aradigm Corp. (ARDM.OB)
On Feb 9:
0.1375 USD
0.00 (0.00%)
MORE ON ARDM.OB
Quotes
Summary
Options
Historical Prices
Charts
Interactive
Basic Chart
Technical Chart
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Major Holders
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheets
Cash Flow
ARADIGM CORP
(OTC BB:ARDM.OB) Delayed quote data
Last Trade:
0.1375 USD
Trade Time:
Feb 9
Change:
0.00 (0.00%)
Prev Close:
0.1375
Open:
N/A
Bid:
N/A
Ask:
N/A
1y Target Est:
2.25
Day's Range:
N/A - N/A
52wk Range:
0.07 - 0.37
Volume:
0
Avg Vol
(3m)
:
223,465
Market Cap:
14.08M
P/E
(ttm)
:
N/A
EPS
(ttm)
:
-0.194
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Add ARDM.OB to Portfolio
Download Data
HEADLINES
Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro*
Business Wire
(Thu, Feb 4)
Aradigm to Present at Biotech Showcase 2010 on January 12
Business Wire
(Wed, Jan 6)
Aradigm Lippert/Heilshorn Life Sciences Call scheduled for 12:00 pm ET today
Vcall
(Tue, Dec 15)
Aradigm to Present at the Lippert/Heilshorn Life Sciences Virtual Conference on December 15
Business Wire
(Thu, Dec 10)
AllPennyStocks.com Announces November 23rd to November 27th U.S. Penny Stocks 2 Watch (LPIH.OB, ARDM.OB)
BayStreet Newswire
(Fri, Nov 20)
Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Br
Business Wire
(Mon, Nov 16)
ARADIGM CORP Financials
EDGAR Online Financials
(Fri, Nov 13)
ARADIGM CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online
(Fri, Nov 6)
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online
(Fri, Aug 7)
ARADIGM CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online
(Thu, Aug 6)
More Headlines for ARDM.OB...
ANALYST
EPS Est (next year)
(Dec-09)
:
-0.14
EPS Est (in 2 years)
(Dec-10)
:
N/A
Avg Rec (current)*:
1.0
PEG Ratio:
N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States.
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Symbol Lookup
Latest News
Canadian Indices